First it missed the boat by greedy pricing 40% more than Zytiga. Most drug plans won't cover it so it will follow DNDN from $45 to $6.. Second, it didn't invent Xtandi. Its original inventor already had a better drug, ARN509 will be soon approved and MDVN lost the patent rights to it. ARN509 has no siezures, fewer side effects and is more effective. MDVN only owns half of one drug and 10% of its profits from Xtandi go to UCLA. Market cap of Xtandi should be $1 Billion but it is currently $10 Billion based on MDVN's price.